<DOC>
	<DOCNO>NCT02837692</DOCNO>
	<brief_summary>The purpose study assess pharmacokinetics single-dose evening administration JNJ-42847922 elderly non-Asian adult compare weight- gender-matched young healthy non-Asian adult assess pharmacokinetics single-dose evening administration JNJ-42847922 healthy Japanese adult .</brief_summary>
	<brief_title>A Study Assess Effects Age Gender Pharmacokinetics JNJ-42847922 Healthy Adults</brief_title>
	<detailed_description />
	<criteria>In Group A : For cohort , 10 elderly nonAsian adult great equal ( &gt; = ) 65 year old , least 2 participant &gt; =70 year &lt; 75 year old , least 2 participant &gt; =75 year old , 5 participant sex ; In Group B : For cohort , 10 young healthy nonAsian adult 18 45 year old , inclusive , match elderly participant cohort gender body weight ( plus [ + ] minus [ ] 5 kilogram [ kg ] ) ; In Group C : For cohort , 10 healthy Japanese adult 20 60 year old , inclusive , reside outside Japan le equal ( &lt; = ) 10 year , parent maternal paternal grandparent Japanese , primarily consume Japanese diet , 5 participant sex Signed informed consent document indicate understand purpose procedure require study willing participate study Group B Group C : If woman , must negative serum betahuman chorionic gonadotropin ( hCG ) pregnancy test screen negative urine pregnancy test Day 1 treatment period Group B Group C : If woman , must agree donate egg ( ovum , oocytes ) purpose assist reproduction study least 3 month last study drug administration If man sexually active woman childbearing potential vasectomy , must agree use adequate contraception method deem appropriate investigator ( eg , vasectomy , doublebarrier , partner use effective contraception ) donate sperm study 3 month receive last dose study drug Has body mass index ( BMI ) ( weight kilogram [ kg ] /height^2 meter [ ] ^2 ) 18 30 kg/m2 ( inclusive ) body weight less 50 kg nonAsian subject ( Group A Group B ) less 45 kg Japanese subject ( Group C ) Received know inhibitor cytochrome P450 3A4 ( CYP3A4 ) CYP2C9 activity within 28 day period le 5 time drug halflife ; whichever long , first dose study drug schedule Consumption product contain grapefruit Seville oranges within 28 day first dose study drug schedule Received experimental drug use experimental medical device within 1 month within period le 10 time drug 's halflife , whichever longer , first dose study drug schedule Unable swallow solid , oral dosage form whole aid water ( participant may chew , divide , dissolve , crush study drug ) Positive test human immunodeficiency virus ( HIV ) 1 2 antibody , hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>